prophylact
empir
antibiot
use
part
standard
care
highrisk
patient
especi
hematopoiet
cell
transplant
hct
recipi
reduc
risk
morbid
mortal
associ
lifethreaten
bacteri
infect
hand
emerg
data
suggest
antibiot
exposur
affect
advers
transplant
outcom
although
exact
mechan
remain
elus
immunomodulatori
effect
antibiot
via
alter
gut
microbiota
suscept
bacteri
infect
graftversushost
diseas
gvhd
may
plausibl
explan
recent
anim
human
data
demonstr
intrigu
link
antibiot
exposur
microbiota
respiratori
viral
infect
rvi
studi
mice
show
relationship
disrupt
microbiota
impair
immun
control
biolog
blood
marrow
transplant
journal
homepag
wwwbbmtorg
rvi
antibiotictr
mous
model
protect
effect
lactobacillu
prime
lethal
pneumonia
viru
also
human
studi
show
reduc
respiratori
diseas
sever
probiot
use
immunocompet
popul
associ
low
microbiom
divers
pulmonari
complic
includ
viral
pneumonia
hct
recipi
rvi
frequent
associ
lower
respiratori
tract
diseas
lrtd
mortal
hct
recipi
progress
lrtd
may
also
affect
antibiot
exposur
howev
littl
clinic
data
exist
support
hypothesi
object
studi
investig
effect
antibiot
use
respiratori
diseas
progress
follow
rvi
transplant
recipi
hypothes
either
preor
posttranspl
antibiot
exposur
would
increas
risk
diseas
progress
rvi
occur
allogen
hct
retrospect
review
allogen
hct
recipi
whose
first
rvi
diagnos
multiplex
respiratori
viral
pcr
fred
hutchinson
cancer
research
center
fred
hutch
first
day
posttranspl
select
patient
parainfluenza
viru
piv
respiratori
syncyti
viru
rsv
human
metapneumoviru
mpv
detect
respiratori
tract
without
respiratori
copathogen
virus
select
given
wellestablish
respiratori
pathogenesi
popul
influenza
viru
evalu
due
limit
number
case
current
studi
consecut
subject
identifi
cohort
first
cohort
includ
patient
underw
transplant
march
februari
nasal
sampl
collect
test
clinic
purpos
respiratori
symptom
present
second
cohort
subset
prospect
surveil
studi
hct
recipi
undergo
transplant
june
februari
standard
respiratori
symptom
survey
multiplex
respiratori
pcr
test
perform
weekli
first
day
posttranspl
analysi
includ
subject
respiratori
symptom
time
first
detect
respiratori
virus
complet
blood
cell
count
measur
within
week
viru
detect
demograph
clinic
data
extract
fred
hutch
databas
medic
chart
review
studi
approv
institut
review
board
fred
hutch
reversetranscript
pcr
perform
respiratori
virus
respiratori
sampl
describ
previous
proven
probabl
lrtd
provenprob
lrtd
defin
viru
detect
pcr
lower
respiratori
tract
sampl
eg
bronchoalveolar
lavag
without
new
pulmonari
infiltr
chest
radiographi
respect
possibl
lrtd
defin
viru
detect
pcr
upper
respiratori
tract
sampl
new
pulmonari
infiltr
measur
sever
patient
underli
condit
hct
comorbid
index
use
hct
comorbid
index
compris
differ
categori
organ
dysfunct
establish
tool
predict
nonrelaps
overal
mortal
hct
hct
comorbid
index
score
categor
high
risk
score
consid
low
risk
poor
transplant
outcom
date
first
detect
respiratori
virus
upper
respiratori
tract
sampl
consid
date
viral
onset
serv
time
zero
progress
lrtd
outcom
patient
diagnos
lrtd
date
first
detect
viru
time
zero
assign
day
date
analysi
time
defin
number
day
time
zero
lrtd
death
day
follow
viral
onset
whichev
came
first
antibiot
use
viral
onset
main
baselin
exposur
defin
differ
time
window
antibiot
exposur
viral
onset
pretransplant
period
day
day
transplant
immedi
posttransplant
period
day
day
transplant
day
viral
onset
whichev
came
first
immedi
preonset
period
week
prior
day
viral
onset
preand
posttransplant
period
day
transplant
day
viral
onset
supplementari
figur
antibiot
exposur
window
defin
use
specif
antibiot
versu
none
antibiot
averag
number
antibiot
per
day
averag
number
antibiot
per
day
comput
patient
divid
cumul
sum
number
antibiot
receiv
day
time
window
total
antibioticday
number
day
window
antimicrobi
pneumocysti
jiroveci
pneumonia
fungu
exclud
except
trimethoprimsulfamethoxazol
prophylact
use
trimethoprimsulfamethoxazol
typic
continu
day
transplant
resum
engraft
posttransplant
prophylact
use
trimethoprimsulfamethoxazol
count
daili
regimen
pretransplant
twiceweekli
regimen
posttransplant
accord
institut
standard
practic
antibiot
prophylaxi
neutropenia
levofloxacin
adult
ceftazidim
children
standard
practic
begin
onset
neutropenia
continu
engraft
addit
assess
individu
antibiot
trimethoprimsulfamethoxazol
intraven
vancomycin
antibiot
group
base
specif
antimicrobi
activ
interest
follow
antibiot
signific
anaerob
activ
meropenem
imipenem
ertapenem
piperacillintazobactam
ampicillinsulbactam
amoxicillinclavulan
metronidazol
moxifloxacin
clindamycin
antibiot
signific
gram
posit
activ
vancomycin
daptomycin
linezolid
clindamycin
ciprofloxacin
levofloxacin
carbapenem
meropenem
imipenem
ertapenem
antipseudomon
cephalosporin
ceftazidim
cefepim
estim
cumul
incid
respiratori
viral
diseas
progress
lrtd
treat
death
compet
risk
compar
cumul
incid
curv
baselin
antibiot
exposur
previous
mention
time
window
select
window
estim
associ
antibiot
exposur
progress
lrtd
unadjust
adjust
cox
proport
hazard
model
provenprob
lrtd
provenprobableposs
lrtd
analyz
separ
outcom
separ
model
baselin
covari
potenti
confound
select
previous
identifi
risk
factor
diseas
progress
import
biolog
variabl
factor
thought
influenc
antibiot
use
neutropenia
window
antibiot
exposur
measur
covari
test
associ
lrtd
use
univari
cox
model
novel
gvhd
prophylact
strategi
includ
cell
deplet
alemtuzumab
abatacept
standard
practic
analyz
studi
due
limit
number
event
multivari
model
consid
combin
proven
probableposs
lrtd
outcom
includ
maximum
variabl
antibiot
exposur
overal
individu
antibiot
specif
group
antibiot
analyz
separ
model
use
approach
outlin
subsequ
guid
select
confound
associ
antibiot
exposur
progress
lrtd
propos
direct
acycl
graph
dag
use
set
minim
suffici
adjust
variabl
identifi
dag
select
covari
inclus
multivari
model
due
high
correl
lymphopenia
monocytopenia
viral
onset
includ
variabl
separ
multivari
model
select
time
window
number
day
patient
estim
averag
number
antibiot
per
day
report
hazard
ratio
hr
increas
number
antibioticday
easier
interpret
proport
hazard
assumpt
assess
graphic
check
base
martingal
residu
test
interact
logarithm
analysi
time
covari
address
concern
antibiot
use
rapidli
progress
respiratori
ill
immedi
defin
date
viral
onset
perform
sensit
analys
shift
time
window
end
day
viral
onset
rather
day
onset
twosid
p
valu
consid
statist
signific
statist
analys
perform
use
sa
window
sa
institut
inc
cari
nc
identifi
adult
pediatr
hct
recipi
fulfil
studi
criteria
piv
rsv
mpv
tabl
time
viral
onset
follow
hct
evenli
distribut
first
day
median
day
interquartil
rang
day
rel
high
hct
comorbid
index
score
score
steroid
use
common
cohort
relaps
underli
malign
occur
patient
viral
onset
neither
receiv
chemotherapi
relaps
patient
receiv
least
antibiot
preand
posttransplant
period
viral
onset
number
patient
receiv
antibiot
window
follow
pretransplant
period
immedi
posttransplant
period
immedi
preonset
period
supplementari
figur
show
distribut
averag
number
antibiot
per
day
patient
specifi
time
window
median
pretransplant
period
immedi
posttransplant
period
immedi
preonset
period
preand
posttransplant
period
trimethoprimsulfamethoxazol
levofloxacin
ceftazidim
commonli
use
window
immedi
posttransplant
period
trimethoprimsulfamethoxazol
rare
use
expect
base
standard
clinic
protocol
supplementari
figur
distribut
averag
number
antibiot
per
day
accord
individu
antibiot
group
antibiot
interest
compar
window
supplementari
figur
antibiot
interest
trimethoprimsulfamethoxazol
frequent
administ
immedi
posttransplant
period
patient
progress
provenprobableposs
lrtd
provenprob
lrtd
among
patient
progress
lrtd
observ
median
number
day
onset
progress
day
interquartil
rang
day
six
patient
diagnos
lrtd
date
first
detect
diagnos
possibl
lrtd
figur
show
cumul
incid
proven
probableposs
lrtd
tertil
overal
averag
number
antibiot
per
day
window
largest
separ
curv
high
antibiot
exposur
group
lowerexposur
group
observ
immedi
data
present
n
median
rang
clinic
cohort
patient
test
symptomat
surveil
cohort
patient
test
weekli
regardless
symptom
patient
respiratori
symptom
viral
onset
select
z
time
transplant
x
use
minimum
valu
per
patient
time
window
k
use
nearest
valu
within
wk
viral
onset
proport
day
per
patient
lymphocyt
count
proport
day
per
patient
neutrophil
count
proport
day
per
patient
monocyt
count
yy
bacteria
fungi
grow
blood
cultur
viral
onset
except
contamin
preonset
period
week
prior
day
viral
onset
use
window
note
similar
pattern
cumul
incid
curv
sever
group
antibiot
individu
antibiot
supplementari
figur
trend
promin
seen
window
consid
data
shown
base
descript
curv
chose
immedi
preonset
period
estim
effect
antibiot
exposur
lrtd
outcom
use
cox
proport
hazard
model
associ
progress
lrtd
univari
model
estim
associ
progress
provenprob
lrtd
provenprobableposs
lrtd
shown
figur
cumul
antibiot
exposur
number
antibioticday
exposur
ciprofloxacinlevofloxacin
associ
increas
risk
diseas
progress
model
overal
trend
hr
similar
provenprobableposs
lrtd
proven
probabl
lrtd
alon
outcom
hr
provenprob
lrtd
alon
higher
specif
antibiot
group
eg
vancomycinlinezoliddaptomycin
proven
probableposs
lrtd
addit
antibiot
exposur
leukopenia
lymphopenia
monocytopenia
neutropenia
week
viral
onset
associ
increas
risk
diseas
progress
contrast
factor
measur
pretransplant
eg
age
condit
regimen
leukopenia
found
signific
viral
onset
first
day
posttranspl
significantli
associ
higher
risk
provenprobableposs
lrtd
outcom
thought
mainli
driven
leukopenia
immedi
hct
base
first
propos
dag
figur
evalu
multivari
model
adjust
lymphopenia
viral
onset
neutropenia
frequenc
week
onset
steroid
use
week
onset
also
ran
similar
model
includ
monocytopenia
onset
instead
lymphopenia
set
model
provid
similar
result
figur
cumul
antibiot
exposur
remain
significantli
associ
progress
provenprobableposs
lrtd
hr
similar
unadjust
estim
antibiot
signific
anaerob
activ
carbapenem
ciprofloxacinlevofloxacin
adjust
estim
associ
progress
lrtd
longer
statist
signific
second
propos
dag
similar
first
dag
ad
assumpt
patient
complic
clinic
statu
measur
hct
comorbid
index
like
receiv
antibiot
like
progress
lrtd
figur
set
adjust
variabl
identifi
dag
includ
set
list
previou
model
addit
hct
comorbid
index
led
maximum
number
variabl
could
includ
given
limit
number
event
evalu
bivari
model
includ
hct
comorbid
index
antibiot
exposur
variabl
antibiot
estim
chang
substanti
data
shown
indic
hct
comorbid
index
substanti
confound
effect
associ
antibiot
exposur
progress
lrtd
separ
perform
sensit
analys
use
modifi
immedi
preonset
period
week
day
viral
onset
result
remain
similar
supplementari
figur
pretransplant
period
day
day
transplant
immedi
posttransplant
period
day
day
transplant
day
viral
onset
whichev
came
first
immedi
preonset
period
week
prior
day
viral
onset
preand
posttransplant
period
day
transplant
day
viral
onset
p
valu
base
gray
test
result
support
hypothesi
prior
antibiot
exposur
may
impact
diseas
sever
respiratori
virus
allogen
transplant
recipi
cumul
antibiot
exposur
immedi
prior
onset
piv
rsv
mpv
upper
respiratori
infect
associ
increas
risk
progress
lrtd
adjust
model
exposur
specif
antibiot
significantli
associ
increas
risk
progress
recent
random
control
trial
indic
even
shortterm
antibiot
use
may
lead
signific
chang
gut
microbiota
antibiot
exposur
low
microbiom
divers
increasingli
recogn
import
risk
factor
poor
transplant
outcom
includ
gvhd
bacteri
infect
potenti
advers
impact
antibiot
exposur
transplant
outcom
highlight
recent
random
trial
azithromycin
prophylaxi
given
year
posttransplant
result
wors
airflow
declinefre
surviv
higher
rate
hematolog
relaps
compar
placebo
alter
microbiota
induc
antibiot
use
may
play
role
immun
modif
transplant
outcom
interestingli
rate
diseas
progress
lrtd
vari
wide
piv
rsv
mpv
depend
surveil
measur
transplant
center
find
rais
question
whether
differ
antibiot
practic
transplant
center
may
import
reason
observ
differ
progress
rate
epidemiolog
link
observ
current
studi
may
provid
rational
probe
impact
microbiota
transplant
outcom
includ
respiratori
viral
diseas
progress
premis
consist
recent
publish
data
show
abund
butyrateproduc
bacteria
neg
correl
respiratori
viral
diseas
progress
transplant
outcom
evalu
futur
studi
antimicrobi
deescal
strategi
differ
antibiot
util
strategi
strategi
modifi
microbiom
respiratori
diseas
progress
could
assess
import
endpoint
guid
cumul
incid
curv
lrtd
chose
immedi
preonset
period
estim
effect
antibiot
exposur
lrtd
outcom
provenprobableposs
lrtd
provenprob
lrtd
figur
univari
model
estim
associ
progress
provenprobableposs
lower
respiratori
tract
diseas
fill
squar
repres
hr
bar
repres
confid
interv
lower
confid
limit
lcl
upper
confid
limit
ucl
estim
shown
black
repres
unadjust
estim
associ
progress
provenprob
lrtd
provenprob
lrtd
event
estim
shown
gray
repres
unadjust
estim
associ
progress
provenprobableposs
lrtd
provenprobableposs
lrtd
event
antibiot
exposur
week
prior
day
viral
onset
use
patient
receiv
clindamycin
time
window
hr
number
antibioticday
repres
effect
per
increas
estim
repres
versu
use
specifi
antibiot
antibiot
anaerob
activ
includ
meropenem
imipenem
ertapenem
piperacillintazobactam
ampicillinsulbactam
amoxicillinclavulan
metronidazol
moxifloxacin
clindamycin
hr
age
transplant
repres
effect
per
year
age
older
estim
condit
regimen
compar
nonmyeloabl
myeloabl
regimen
hct
comorbid
index
compar
valu
precondit
lymphocyt
neutrophil
count
minimum
valu
day
transplant
hr
repres
effect
per
increas
estim
time
transplant
compar
day
day
rvi
onset
lymphopenia
monocytopenia
rvi
onset
defin
nearest
count
within
week
viral
onset
neutropenia
defin
hr
frequenc
neutropenia
repres
effect
per
increas
percentag
day
neutropenia
figur
direct
acycl
graph
describ
hypothet
model
relationship
main
exposur
antibiot
use
week
prior
day
viral
onset
outcom
provenprobableposs
lower
respiratori
tract
diseas
green
variabl
repres
ancestor
exposur
blue
variabl
repres
ancestor
outcom
red
variabl
repres
ancestor
exposur
outcom
gray
variabl
indic
unmeasur
variabl
studi
green
arrow
show
causal
path
need
estim
red
arrow
show
bias
path
need
block
estim
causal
associ
framework
minim
suffici
set
adjust
variabl
requir
estim
associ
without
bia
includ
either
lymphopenia
viral
onset
result
may
impli
recent
antibiot
exposur
like
impact
respiratori
diseas
progress
distant
antibiot
exposur
fact
mice
show
diminish
immun
respons
influenza
viru
inocul
immedi
cours
antibiot
import
note
magnitud
report
associ
overal
antibiot
exposur
lrtd
adjust
hr
repres
increas
risk
associ
increas
match
short
cours
antibiot
longer
concurr
antibiot
cours
would
associ
higher
risk
exampl
estim
hr
unit
increas
averag
number
antibiot
per
day
would
nearli
chose
examin
associ
antibiot
class
base
spectrum
antimicrobi
activ
might
provid
deeper
insight
mechan
action
exampl
antibiot
activ
clostridial
gramposit
anaerob
bacteria
associ
increas
risk
gvhd
transplantrel
mortal
use
clostridialesspar
antibiot
propos
current
studi
demonstr
statist
signific
associ
use
specif
antibiot
class
progress
provenprobableposs
lrtd
adjust
model
although
trend
observ
use
certain
antibiot
group
eg
antibiot
signific
anaerob
activ
carbapenem
increas
risk
progress
adjust
potenti
confound
base
dag
includ
previous
identifi
risk
factor
diseas
progress
import
biolog
variabl
factor
presum
relat
antibiot
use
case
dag
illustr
import
leukopenia
steroid
use
confound
variabl
like
associ
exposur
antibiot
use
outcom
diseas
progress
due
small
number
event
unabl
adjust
full
set
variabl
identifi
second
propos
dag
tri
address
concern
sicker
patient
monocytopenia
viral
onset
frequenc
neutropenia
week
viral
onset
steroid
use
week
viral
onset
time
transplant
viral
onset
frequenc
neutropenia
week
viral
onset
steroid
use
week
viral
onset
b
model
minim
suffici
set
adjust
variabl
requir
estim
associ
without
bia
includ
either
lymphopenia
viral
onset
monocytopenia
viral
onset
frequenc
neutropenia
week
viral
onset
steroid
use
week
viral
onset
hct
comorbid
index
time
transplant
viral
onset
frequenc
neutropenia
week
viral
onset
steroid
use
week
viral
onset
hct
comorbid
index
model
estim
unadjust
adjust
associ
antibiot
exposur
week
prior
day
viral
onset
progress
provenprobableposs
lower
respiratori
tract
diseas
fill
squar
repres
hr
bar
repres
confid
interv
lcl
ucl
estim
shown
black
repres
unadjust
estim
dark
gray
repres
adjust
estim
multivari
model
adjust
percentag
day
neutropenia
week
viral
onset
lymphopenia
viral
onset
steroid
use
week
viral
onset
light
gray
adjust
estim
multivari
model
adjust
percentag
day
neutropenia
week
viral
onset
monocytopenia
viral
onset
steroid
use
week
viral
onset
hr
number
antibioticday
repres
effect
per
increas
estim
repres
versu
use
specifi
antibiot
antibiot
anaerob
activ
includ
meropenem
imipenem
ertapenem
piperacillintazobactam
ampicillinsulbactam
amoxicillinclavulan
metronidazol
moxifloxacin
clindamycin
comorbid
may
like
prescrib
antibiot
progress
lrtd
howev
bivari
model
includ
hct
comorbid
index
antibiot
exposur
show
evid
confound
effect
hct
comorbid
index
therefor
think
unlik
full
multivari
model
includ
hct
comorbid
index
would
give
substanti
differ
result
adjust
estim
present
current
studi
patient
diagnos
lrtd
date
first
detect
respiratori
virus
possibl
antibiot
actual
given
context
rapidli
progress
respiratori
ill
despit
definit
relev
window
interest
antibiot
exposur
end
least
day
viral
onset
therefor
also
perform
sensit
analys
use
modifi
immedi
preonset
period
week
day
viral
onset
result
remain
consist
main
limit
studi
rel
small
sampl
size
singl
transplant
center
despit
attempt
combin
provenprob
lrtd
possibl
lrtd
perform
adjust
model
analysi
possibl
studi
underpow
adequ
evalu
impact
specif
antibiot
class
although
possibl
lrtd
use
lrtd
numer
studi
would
ideal
appli
strict
criteria
increas
certainti
microbiolog
diagnosi
lrtd
studi
hr
provenprob
lrtd
alon
higher
group
exposur
antibiot
eg
vancomycin
linezolid
daptomycin
provenprob
possibl
lrtd
similar
adjust
model
outcom
provenprob
lrtd
alon
perform
among
larger
cohort
patient
event
might
see
larger
effect
antibiot
furthermor
unabl
examin
doserespons
relationship
specif
antibiot
class
determin
whether
observ
differ
individu
virus
final
despit
effort
adjust
confound
use
dag
possibl
factor
differ
causal
diagram
may
explain
relationship
antibiot
exposur
lrtd
unrecogn
confound
complet
elimin
due
natur
retrospect
studi
first
studi
demonstr
cumul
antibiot
exposur
immedi
prior
viral
onset
appear
import
risk
factor
diseas
progress
respiratori
virus
transplant
recipi
larger
cohort
studi
need
determin
whether
exposur
specif
antibiot
class
increas
risk
diseas
progress
whether
differ
respiratori
virus
ultim
random
clinic
trial
differ
antibiot
util
strategi
strategi
modifi
microbiom
need
